• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Minerals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks
    biotech investing

    NOTICE FROM FIRM THAT FILED THE LAWSUIT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BELLUS Health Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    Written by Investing News Network
    |
    Mar. 22, 2021 02:30PM PST
    The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against BELLUS Health Inc. for violations of §§10 and 20 of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange CommissionInvestors who purchased the Company's securities between September 5, 2019 and July 5, 2020, inclusive are encouraged to ...

    The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against BELLUS Health Inc. ("BELLUS" or "the Company") (NASDAQ: BLU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission

    Investors who purchased the Company's securities between September 5, 2019 and July 5, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before May 17, 2021.

    If you are a shareholder who suffered a loss, click here to participate.

    We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

    The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

    According to the Complaint, the Company made false and misleading statements to the market. BELLUS misrepresented and/or failed to disclose that BLU-5937's "high selectivity" contributed to the drug potentially being less efficacious and thus likely unable to meet the primary endpoint of the Company's Phase 2 study. As a result, when Defendants announced before markets opened on July 6, 2020, that BLU-5937 had failed the Phase 2 study, the Company's stock price plummeted over 75% on heavy trading volume. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about BELLUS, investors suffered damages.

    Join the case to recover your losses.

    The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

    This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

    CONTACT:

    The Schall Law Firm
    Brian Schall, Esq.,
    www.schallfirm.com
    Office: 310-301-3335
    info@schallfirm.com

    SOURCE: The Schall Law Firm



    View source version on accesswire.com:
    https://www.accesswire.com/636919/NOTICE-FROM-FIRM-THAT-FILED-THE-LAWSUIT-The-Schall-Law-Firm-Announces-the-Filing-of-a-Class-Action-Lawsuit-Against-BELLUS-Health-Inc-and-Encourages-Investors-with-Losses-in-Excess-of-100000-to-Contact-the-Firm

    News Provided by ACCESSWIRE IA via QuoteMedia

    bellus healthblu:cablubiotech investingbiotech investing
    The Conversation (0)

    Go Deeper

    AI Powered

    Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against BELLUS Health Inc.

    BELLUS Health Inc.

    BELLUS Health Inc.

    Latest News

    Lexaria Updates Financial Position

    More News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    BriaCell Therapeutics

    BriaCell Therapeutics (BCT:CC)
    BCT:CC

    Lexaria Bioscience

    Lexaria Bioscience (LEXX)
    LEXX
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES